AMRXAmneal Pharmaceuticals, Inc.
What is the market doing?
No clear lean: nothing decisive, though in an uptrend.
In an uptrend, above its rising 50- and 200-day averages. Price is +34% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Moderately shorted, settled Sep 15, 2026, about a week of normal trading to cover. Up 6.8% since the previous count, up from 2.4% of shares outstanding three months ago.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How AMRX is trading
Amneal Pharmaceuticals, Inc. is +103% over the past year while the S&P 500 is +18%: 85 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +34%
vs 200-day average · a clear uptrend
- RSI (14)
- 47
RSI (14) · neutral
- Below its 52-week high
- 2.8%
Below its 52-week high
Details›
- Last close2026-10-09
- $19.92
- 1 monthS&P 500 +2.7%
- +18%
- 1 yearS&P 500 +18%
- +103%
- 5 yearsS&P 500 +88%
- +303%
- vs 50-day average$18.48
- +7.8%
- 52-week high
- $20.49
- 52-week low
- $9.60
- Annualised volatility
- 35%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$7.7M
| Year | Return |
|---|---|
| 2026 (year to date) | +58% |
| 2025 | +59% |
| 2024 | +30% |
| 2023 | +205% |
| 2022 | −58% |
| 2021 | +4.8% |
| 2020 | −5.2% |
| 2019 | −64% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 8 | 4 of 8 | −0.85% |
| Feb | 8 | 6 of 8 | +1.6% |
| Mar | 8 | 3 of 8 | −3.0% |
| Apr | 8 | 3 of 8 | +0.40% |
| May | 8 | 5 of 8 | +2.4% |
| Jun | 9 | 3 of 9 | +2.6% |
| Jul | 9 | 5 of 9 | −1.1% |
| Aug | 9 | 5 of 9 | +2.5% |
| Sep | 9 | 4 of 9 | +1.2% |
| Oct | 9 | 6 of 9 | +0.98% |
| Nov | 8 | 4 of 8 | +3.8% |
| Dec | 8 | 5 of 8 | +6.2% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Drug Manufacturers, Specialty & Generic
Ranks #16 of 41 by RyuScore